← Leaderboards
Qi Zhou
Purdue University
$3,430,421
Attributed
$6,860,842
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,860,842 · 3
By mechanism
R01$6,860,842 · 3
Top collaborators
- Jian Li11 shared
Most similar at Purdue University
Same institution · by research overlap
- Stephen J. Kron$22,590,323
- Yoon Yeo$6,785,486
- Elias I Franses$1,212,500
Others in their field
Other Emerging Leaders on “Powder Dose Form”
- Bryce Beverlin II · Quench Medical, Inc.$5,631,185
- Sylvain Fleury · Texas Biomedical Research Institute$4,420,400
- Barney Sparrow · Battelle Memorial Institu$4,131,523
- Matthew Reed · Nob Hill Therapeutics, Inc.$4,021,634
- Edward Burgard · Dignify Therapeutics, Llc$3,912,777
- John Koleng · Via Therapeutics, Llc$3,599,145
Research focus
Powder Dose FormPublic Health RelevancePolymyxinsPolymyxin ResistanceInnovationLungNebulizerFormulationPathogenPharmacodynamicsCombined Modality TherapyInhalation TherapyAntibioticsInterdisciplinary ApproachNational Institute Of Allergy And Infectious DiseaseMultidisciplinaryClinicDrug KineticsAerosolsDosageCombatPharmaceutical PreparationsAdverse EffectsRegimen
Grant awards (11)
Aerosol delivery of combinational therapeutics targeting deadly lung infections$594,930
R01 · FY2025 · HL · contact PI
Aerosol delivery of combinational therapeutics targeting deadly lung infections$614,933
R01 · FY2024 · HL · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$646,188
R01 · FY2023 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$639,543
R01 · FY2022 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$646,174
R01 · FY2021 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$642,515
R01 · FY2020 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$573,080
R01 · FY2020 · AI · contact PI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs$673,485
R01 · FY2019 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$565,399
R01 · FY2019 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$614,336
R01 · FY2018 · AI · contact PI
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems Approach$650,259
R01 · FY2017 · AI · contact PI